- Home
- OPT vs CYH Comparison
OPT vs CYH Comparison
Compare OPT & CYH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- OPT
- CYH
- Stock Information
- Founded
- OPT 1984
- CYH 1985
- Country
- OPT Australia
- CYH United States
- Employees
- OPT N/A
- CYH N/A
- Industry
- OPT Biotechnology: Biological Products (No Diagnostic Substances)
- CYH Hospital/Nursing Management
- Sector
- OPT Health Care
- CYH Health Care
- Exchange
- OPT Nasdaq
- CYH Nasdaq
- Market Cap
- OPT 767.9M
- CYH 623.8M
- IPO Year
- OPT 2020
- CYH 1991
- Fundamental
- Price
- OPT $3.24
- CYH $3.85
- Analyst Decision
- OPT Strong Buy
- CYH Hold
- Analyst Count
- OPT 1
- CYH 5
- Target Price
- OPT $12.00
- CYH $5.20
- AVG Volume (30 Days)
- OPT 39.0K
- CYH 2.5M
- Earning Date
- OPT 08-30-2024
- CYH 10-23-2024
- Dividend Yield
- OPT N/A
- CYH N/A
- EPS Growth
- OPT N/A
- CYH N/A
- EPS
- OPT N/A
- CYH N/A
- Revenue
- OPT $261,859.00
- CYH $12,551,000,000.00
- Revenue This Year
- OPT N/A
- CYH $1.19
- Revenue Next Year
- OPT $46,864.64
- CYH $1.48
- P/E Ratio
- OPT N/A
- CYH N/A
- Revenue Growth
- OPT N/A
- CYH 0.81
- 52 Week Low
- OPT $1.79
- CYH $2.31
- 52 Week High
- OPT $5.45
- CYH $6.29
- Technical
- Relative Strength Index (RSI)
- OPT 27.29
- CYH 30.86
- Support Level
- OPT $4.02
- CYH $4.08
- Resistance Level
- OPT $4.18
- CYH $4.64
- Average True Range (ATR)
- OPT 0.22
- CYH 0.26
- MACD
- OPT -0.13
- CYH -0.02
- Stochastic Oscillator
- OPT 6.85
- CYH 7.02
About OPT Opthea Limited
Opthea Ltd operates in one industry being the medical technology and healthcare. It is focused on developing biological therapeutics for eye diseases. The company is developing a novel biologic therapy, OPT-302, for the treatment of eye diseases. Its products are based on the intellectual property portfolio covering Vascular Endothelial Growth Factors C and D and R3 targets. Opthea's development activities are based on an intellectual property portfolio covering key targets Vascular Endothelial Growth Factors VEGF-C, VEGF-D and VEGF Receptor-3 for the treatment of diseases associated with blood and lymphatic vessel growth, as well as vascular leakage. The company geographically operates Australia and United States.
About CYH Community Health Systems Inc.
Community Health Systems Inc is a publicly owned hospital operator in the United States. The company also owns four home health agencies and provides management and consulting services to independent hospitals. The firm derives revenue through a broad range of general and specialized hospital healthcare services and outpatient services.